Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 18/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 17/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.56 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15709394 | 0.86 | HSD11B1 (0.50) | SLC6A4SLC6A3SLC6A2HSD11B1 | |
| SCHEMBL17761306 | 0.86 | SLC6A3 (0.64) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL11107936 | 0.83 | SLC6A3 (0.56) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL17761317 | 0.83 | SLC6A3 (0.64) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL624643 | 0.81 | HSD11B1 (0.63) | SLC6A4SLC6A3SLC6A2HSD11B1 | |
| SCHEMBL5086399 | 0.81 | SLC6A3 (0.65) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL5084070 | 0.81 | SLC6A4 (0.60) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL27997201 | 0.80 | SLC6A4 (0.74) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL9466435 | 0.79 | SLC6A4 (0.56) | SLC6A4SLC6A3SLC6A2HSD11B1 | |
| SCHEMBL15709573 | 0.79 | HSD11B1 (0.45) | SLC6A4SLC6A3SLC6A2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9156788-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2015-10-13 | — | — | US | disclosed |
| EP-2603490-A1 | NOVEL TRPV3 MODULATORS | AbbVie Inc. (US) | 2013-06-19 | — | — | EP | disclosed |
| US-20130150409-A1 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2013-06-13 | — | — | US | disclosed |
| CN-103140476-A | Novel trpv3 modulators | ABBOTT LAB | 2013-06-05 | — | — | CN | disclosed |
| WO-2012019315-A1 | NOVEL TRPV3 MODULATORS | ABBOTT LABORATORIES (US) | 2012-02-16 | — | — | WO | disclosed |
| US-4629727-A | ANTIDEPRESSANTS | THE BOOTS COMPANY PLC (GB) | 1986-12-16 | — | — | US | disclosed |
| EP-0111994-B1 | (1-ARYLCYCLOBUTYL) ALKYLAMINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS THERAPEUTIC AGENTS | The Boots Company PLC (GB) | 1986-02-26 | — | — | EP | disclosed |
| EP-0111994-A1 | (1-Arylcyclobutyl) alkylamine derivatives, their preparation and their use as therapeutic agents | The Boots Company PLC (GB) | 1984-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150409-A1 | NOVEL TRPV3 MODULATORS | TRPV3, TRPV4, TRPV5 | SLC6A4 511/4885SLC6A3 717/4885SLC6A2 1774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.